Release of exotoxin A, peptidoglycan and endotoxin after exposure of clinical Pseudomonas aeruginosa isolates to carbapenems in vitro

Chemotherapy

Volumn 51, Issue 6, 2005, Pages 324-331

  Horii, Toshinobu ^a   Muramatsu, Hideaki ^a   Monji, Akio ^a,b   Miyagishima, Daisuke ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carbapenems; Endotoxin; Exotoxin A; Peptidoglycan; Pseudomonas aeruginosa

Indexed keywords

BIAPENEM; CARBAPENEM; ENDOTOXIN; EXOTOXIN; IMIPENEM; MEROPENEM; PANIPENEM; PEPTIDOGLYCAN;

ARTICLE; BACTERIAL CELL; BACTERIUM CULTURE; BACTERIUM ISOLATE; CELL COUNT; CELL SHAPE; CELL STRUCTURE; CELL VIABILITY; CORRELATION ANALYSIS; CYTOLYSIS; DRUG EFFECT; EXPOSURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SUPERNATANT; TIME;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; CARBAPENEMS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; EXOTOXINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDOGLYCAN; PSEUDOMONAS AERUGINOSA; TIME FACTORS; VIRULENCE FACTORS;

EID: 27544513458     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088955     Document Type: Article

References (32)

1. Pollack M: Pseudomonas aeruginosa; in Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases. New York, Churchill Livingstone, 2000, pp 2310-2335.
2. Dos Santos C, Capelo A, Cimbro M, Ferrara A: Antimicrobial resistance patterns in respiratory pathogens isolated in an Italian university hospital during a period of eight years: A statistical analysis. Chemotherapy 2000;46:166-172.
3. Bonfiglio G, Marchetti F: In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams. Chemotherapy 2000;46:229-234.
4. Erdem I, Kucukercan M, Ceran N: In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. Chemotherapy 2003;49:294-297.
5. Vasil ML: Pseudomonas aeruginosa: Biology, mechanisms of virulence, epidemiology. J Pediatr 1986;108:800-805.
6. Hirakata Y, Kirikae T, Kirikae F, Yamaguchi T, Izumikawa K, Takemura H, Maesaki S, Tomono K, Yamada Y, Kamihira S, Nakano M, Kitamura S, Kohno S: Effect of Pseudomonas aeruginosa exotoxin A on endotoxin-induced tumor necrosis factor production in murine lung. J Med Microbiol 1999;48:471-477.
7. Jaffar-Bandjee MC, Lazdunski A, Bally M, Carrere J, Chazalette JP, Galabert C: Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa. J Clin Microbiol 1995;33:924-929.
8. Kengatharan KM, De Kimpe S, Robson C, Foster SJ, Thiemermann C: Mechanism of gram-positive shock: Identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthesis, shock, and multiple organ failure. J Exp Med 1998;188:303-315.
9. Kotani S, Takada H, Takahashi I, Ogawa T, Tsujimoto M, Shimauchi H, Ikeda T, Okamura H, Tamura T, Harada K: Immunobiological activities of synthetic lipid A analogs with low endotoxicity. Infect Immun 1986;54:673-682.
10. Iglewski BH, Sadoff JC: Toxin inhibitors of protein synthesis: Production, purification, and assay of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1979;60:780-793.
11. Horii T, Ichiyama S, Ohta M, Kobayashi M: Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa. J Med Microbiol 1999;48,309-315.
12. Misfeldt ML, Legaard PK, Howell SE, Fornella MH, LeGrand RD: Induction of interleukin-1 from murine peritoneal macrophages by Pseudomonas aeruginosa exotoxin A. Infect Immun 1990;58:978-982.
13. Staugas REM, Harvey DP, Ferrante A, Nandoskar M, Allison AC: Induction of tumor necrosis factor (TNF) and interleukin-1 (IL-1) by Pseudomonas aeruginosa and exotoxin A-induced suppression of lymphotoxin, gamma interferon, and IL-1 production in human leukocytes. Infect Immun 1992;60:3162-3168.
14. Zehavi-Willner T: Induction of murine cytotoxic T lymphocytes by Pseudomonas aeruginosa exotoxin A. Infect Immun 1998;56:213-218.
15. Periti P, Mazzei T: New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. Int J Antimicrob Agents 1999;12:97-105.
16. Tracey KJ, Lowry SF: The role of cytokine mediators in septic shock. Adv Surg 1990;23:21-56.
17. Cross AS, Opal SM: Endotoxin's role in Gram-negative bacterial infection. Curr Opin Infect Dis 1995;8:156-163.
18. Nau R, Eiffert H: Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002;15:95-110.
19. Hurley JC: Antibiotic-induced release of endotoxin: A reappraisal. Clin Infect Dis 1992;15:840-854.
20. Prins JM, van Deventer SJH, Kuijper EJ, Speelman P: Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother 1994;38:1211-1218.
21. Horii T, Kobayashi M, Sato K, Ichiyama S, Ohta M: An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of Gram-negative bacilli. J Antimicrob Chemother 1998a;41:435-442.
22. Horii T, Kobayashi M, Nadai M, Ichiyama S, Ohta M: Carbapenem-induced endotoxin release in Gram-negative bacterial sepsis rat models. FEMS Immunol Med Microbiol 1998b;21:297-302.
23. Horii T, Kimura T, Nadai M, Kobayashi M: Lincomycin-induced endotoxin release in Escherichia coli sepsis: Evidence for release in vitro and in vivo. Int J Infect Dis 2000;4:118-122.
24. Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF: Serial quantitation of endotoxemia and bacteremia during therapy for Gram-negative bacterial sepsis. J Infect Dis 1988;157:565-568.
25. Bucklin SE, Morrison DC: Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J Infect Dis 1995;172:1519-1527.
26. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacterials That Grow Aerobically: Approved Standard M7-A5. Wayne, NCCLS, 2000.
27. Jackson JJ, Kropp H: β-Lactam antibiotic-induced release of free endotoxin: In vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 1992;165:1033-1041.
28. Hirakata Y, Furuya N, Tateda K, Kaku M, Yamaguchi K: In vivo production of exotoxin A and its role in endogenous Pseudomonas aeruginosa septicemia in mice. Infect Immun 1993;61:2468-2473.
29. van Langevelde P, van Dissel JT, Ravensbergen E, Appelmelk BJ, Schrijver IA, Groeneveld PHP: Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: Quantitative measurements and biological reactivities. Antimicrob Agents Chemother 1998;42:3073-3078.
30. van Langevelde P, Ravensbergen E, Grashoff P, Beekhuizen H, Groeneveld PHP, van Dissel JT: Antibiotic-induced cell wall fragments of Staphylococcus aureus increase endothelial chemokine secretion and adhesiveness for granulocytes. Antimicrob Agents Chemother 1999;43:2984-2989.
31. Studemeister AE, Quinn JP: Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability. Antimicrob Agents Chemother 1998;42:1267-1268.
32. Livermore DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002;34:634-640.